QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ACAD

QT74ACADIA Pharmaceuticals Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
21.62
+0.02+0.09%
OverviewShort InterestFilings
ACADQT74ACADIA Pharmaceuticals Inc.·NASDAQ
OverviewShort InterestFilings
21.62+0.09%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E9.80EPS (ttm)
2.20
Insider Own46.91%
Shs Outstand171.24M
Perf Week1.08%
Market Cap3.70BForward P/E28.13EPS next Y0.77Insider Trans0.12%Shs Float-Perf Month5.57%
Enterprise Value3.47BPEG0.16EPS next Q0.06Inst Own-Short Float-Perf Quarter4.34%
Income377.27MP/S3.38EPS this Y-82.31%Inst Trans-Short Ratio-Perf Half Y-19.33%
Sales1.10BP/B2.95EPS next Y97.54%ROA23.40%Short Interest-Perf YTD-19.06%
Book/sh7.29P/C29.82EPS next 5Y57.04%ROE35.65%52W High28.35 -23.74%Perf Year-5.18%
Cash/sh4.97P/FCF17.41EPS past 3/5Y-ROIC6.17%52W Low19.69 9.80%Perf 3Y-
Dividend Est.-EV/EBITDA28.66Sales past 3/5Y27.52% 19.39%Gross Margin91.47%Volatility1.72% 1.97%Perf 5Y-
Dividend TTM-EV/Sales3.17EPS Y/Y TTM50.00%Oper. Margin7.39%ATR (14)0.66Perf 10Y-
Dividend Ex-Date-Quick Ratio3.48Sales Y/Y TTM14.41%Profit Margin34.30%RSI (14)51.60Recom2.10
Dividend Gr. 3/5Y-Current Ratio3.59EPS Q/Q-81.82%SMA201.03%Beta1.04Target Price33.67
Payout0.00%Debt/Eq0.04Sales Q/Q9.84%SMA50-0.37%Rel Volume2.00Prev Close21.60
Employees653LT Debt/Eq0.03EarningsAug 05SMA200-7.18%Avg Volume1.61MPrice21.62
IPO DateMay 27, 2004Option/ShortYes / YesEPS/Sales Surpr.-50.00% -4.29%Net Debt/EBITDA-1.91Volume3,225,527Change0.09%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-25-26UpgradeB of A SecuritiesNeutral → Buy
Mar-02-26ReiteratedWilliam Blair$29
Feb-23-26InitiatedWolfe ResearchOutperform$33
Feb-23-26ReiteratedMizuho Securities$29 → $35
Feb-23-26UpgradeMizuhoNeutral → Outperform
Feb-03-26ReiteratedRBC CapitalOutperform$21 → $31
Jan-06-26ReiteratedUBSBuy$35 → $40
Jan-05-26ReiteratedNeedhamBuy$29 → $34
Dec-16-25ReiteratedPiper SandlerOverweight$37
Dec-16-25ReiteratedStifel NicolausHold$25 → $37
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,0961,072958
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A948982
Gross Profit1,002983876
Selling, General and Administrative Excl. Other594549488
Research and Development328329303
Other Operating Expense-20-146
Operating Income80105231
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-35-34147
Net Income Before Taxes115139258
Income Taxes-260-25232
Consolidated Net Income377391226
Net Income From Continuing Operations377391226
Net Income377391226
EPS (Recurring)2.232.321.37
EPS (Basic, Before Extraordinaries)2.232.321.37
EPS (Diluted)2.202.291.36
EBITDA127151100
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio9.8311.66—
Price To Sales Ratio3.374.21—
Gross Margin91.4291.7091.44
Operating Margin7.309.7924.11
Net Margin34.4036.4723.59
Shares Outstanding171169166
Market Capitalization3,6974,514—
Operating Lease Expense
———
Insider Trading Volume
$22.95$20.80$18.66$16.51$14.36● Close Price0.00M0.25M0.51M0.76M1.01MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Brege LauraDirectorMay 29 '26Option Exercise0.0016,214023,202Jun 01 12:00 AM
Ndu AdoraDirectorMay 29 '26Option Exercise0.0016,214032,908Jun 01 12:00 AM
HARRIGAN EDMUNDDirectorMay 29 '26Option Exercise0.0016,214043,148Jun 01 12:00 AM
Poole JonathanDirectorMay 29 '26Option Exercise0.004,02002,010Jun 01 12:00 AM
GAROFALO ELIZABETH A.DirectorMay 29 '26Option Exercise0.0016,214033,489Jun 01 12:00 AM
Daly James MDirectorMay 29 '26Option Exercise0.0016,214012,148Jun 01 12:00 AM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 26 '26Sale21.185,401114,39324,509May 27 12:00 AM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 04 '26Sale21.793,50676,39666,145May 05 12:00 AM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 04 '26Sale21.791,33229,02429,129May 05 12:00 AM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 01 '26Option Exercise0.005,192030,461May 05 12:00 AM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 01 '26Option Exercise0.0013,630069,651May 05 12:00 AM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERApr 07 '26Sale22.201,03022,86627,865Apr 07 12:00 AM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERApr 07 '26Sale22.202,70960,14062,836Apr 07 12:00 AM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERApr 05 '26Option Exercise0.004,020028,895Apr 07 12:00 AM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERApr 05 '26Option Exercise0.0010,552065,545Apr 07 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR